AMPH240920C45000
- 3.51
- -0.49-12.25%
Amphastar Pharmaceuticals Newsroom
Insider Sale: Director Floyd Petersen Sells Shares of Amphastar Pharmaceuticals Inc (AMPH)
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
'Trump Trade' vs. 'Harris Trade': How They Could Shape Your Portfolio
Express News | Amphastar Pharmaceuticals: Armstrong, Genreach to Collaborate to Expand Distribution of Co’s Inhalation Product, Primatene Mist in Mainland China
Express News | Amphastar Pharmaceuticals: On Aug 28 Armstrong Pharmaceuticals & Hong Kong Genreach Limited Entered Into Distribution Agreement
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
'Bottom-fishing' Ideas Within Piper Sandler's Universe of Stocks
Stocks With Three Weeks of Improving Technicals by Piper Sandler
Capital One Financial Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $70
Amphastar Pharmaceuticals Poised for Growth: Strong Product Performance and Strategic Financial Health Drive Buy Rating
Amphastar Pharmaceuticals Insider Sold Shares Worth $736,550, According to a Recent SEC Filing
Express News | Amphastar Pharmaceuticals Inc : Jefferies Cuts Target Price to $55 From $62
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Amphastar Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Express News | Amphastar Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results
Amphastar Pharmaceuticals (AMPH) Gets a Buy From Piper Sandler
Amphastar Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Amphastar Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Revolution Medicines (RVMD) and Personalis (PSNL)